Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme I for Sudden Sensorineural Hearing Loss
NCT05849519Phase 1Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotinamide adenine dinucleotide in sudden sensorineural hearing loss (SSHL), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pure Tone Average at 90 days. Status: unknown.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT05849519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849519.